COYA Company Profile and Key Details

Q: Who are the executives of COYA?

Dr. Fred Grossman D.O., FAPAPres & Chief Medical OfficerDr. Howard Berman Ph.D.Chairman & Chief Executive OfficerMr. Aaron Thome Ph.D.Head of Neuroinflammation PlatformDr. Adrian J. Hepner M.D., Ph.D.Pres & Chief Medical OfficerDr. Gregory MacMichael Ph.D.Chief Technical OfficerMr. David S. SnyderChief Financial Officer & Chief Operating OfficerDr. Michelle Frazier Ph.D.Senior Vice President of Regulatory AffairsDr. Arun Swaminathan Ph.D.Chief Bus. Officer

NASDAQ : COYA

Coya Therapeutics

$4.84

0.42+9.50%

At Close 4:00 PM

61.94

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Coya Therapeutics, Inc. (COYA) stock surged +9.50%, trading at $4.84 on NASDAQ, up from the previous close of $4.42. The stock opened at $4.43, fluctuating between $4.43 and $4.88 in the recent session.

Stock Snapshot

4.42

Prev. Close

80.42M

Market Cap

4.43

Day Low

-4.36

P/E Ratio

-1.11

EPS (TTM)

-0.78

Cash Flow per Share

4.43

Open

16.62M

Number of Shares

4.8781

Day High

92.86%

Free Float in %

2.47

Book Value

110.27K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 06, 2026	4.43	4.88	4.43	4.84	110.27K
Feb 05, 2026	4.71	4.80	4.41	4.42	207.47K
Feb 04, 2026	4.84	4.97	4.67	4.76	168.33K
Feb 03, 2026	4.71	4.94	4.69	4.86	165.35K
Feb 02, 2026	4.62	4.87	4.62	4.74	206.14K
Jan 30, 2026	4.68	4.85	4.50	4.65	272.59K
Jan 29, 2026	4.57	4.76	4.45	4.60	190.99K
Jan 28, 2026	4.86	4.86	4.50	4.60	315.38K
Jan 27, 2026	4.69	4.86	4.66	4.84	79.67K
Jan 26, 2026	4.66	4.77	4.51	4.68	212.89K
Jan 23, 2026	4.73	4.82	4.56	4.72	304.84K
Jan 22, 2026	4.54	4.76	4.49	4.73	212.57K
Jan 21, 2026	4.48	4.64	4.37	4.55	302.02K
Jan 20, 2026	4.21	4.56	4.01	4.48	351.5K
Jan 16, 2026	4.11	4.37	4.06	4.28	385.03K
Jan 15, 2026	4.63	4.73	3.94	4.03	1.03M
Jan 14, 2026	4.69	4.95	4.62	4.64	277.06K
Jan 13, 2026	4.75	4.85	4.45	4.62	323.92K
Jan 12, 2026	4.88	4.88	4.55	4.75	364.73K
Jan 09, 2026	5.15	5.15	4.78	4.85	576.64K

Contact Details

Houston, TX 77057

United States

https://www.coyatherapeutics.com 800 587 8170

About Company

Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Stock Peers

ARGX

-8.86-1.08%

argenx SE$811.45 REGN

18.88+2.46%

Regeneron Pharmaceuticals, Inc.$785.51 UTHR

6.43+1.34%

United Therapeutics Corporation$485.36 VRTX

19.11+4.17%

Vertex Pharmaceuticals Incorporated$477.92 MDGL

14.18+3.06%

Madrigal Pharmaceuticals, Inc.$477.60 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

-3.08-0.93%

Alnylam Pharmaceuticals, Inc.$328.16 PRAX

13.95+4.56%

Praxis Precision Medicines, Inc.$319.57 KRYS

5.1+1.91%

Krystal Biotech, Inc.$272.74 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Coya Therapeutics, Inc. (NASDAQ:COYA) closed at $4.84 USD, gaining $0.42 (9.50%) from the previous close of $4.42. The stock is currently mid-range between its 52-week high and low $3.94 and $8.29. With a market capitalization of about $80.42 million, Coya Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.27). Key stats such as the average daily volume over the past year has been around 240.65 thousand shares, volume is running light vs its 52-week average. Headquartered in Houston, TX, Coya Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Arun Swaminathan, the company employs approximately 8 people and listed since December 29, 2022. Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs).

Technical Performance

COYA has shown weak momentum, losing -5.68% over the past week and -29.56% over the past quarter, though year-to-date performance is down -22.76%. Short-term trend indicators are bullishly aligned (SMA20 4.49%, SMA50 -9.03%, SMA200 -17.46%). The stock’s 14-day RSI is 49.13 (neutral), while the ATR of 0.35 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -41.62% below its high and over 22.84% above its low. Average 10-day trading volume of 190.69 thousand shares is below the 3-month average of 231.90 thousand, indicating normal recent market interest.

Valuation Metrics

Coya Therapeutics, Inc. trades at a P/E ratio of -4.41, slightly below the S&P 500 average, with a price-to-sales ratio of 20.23 and a price-to-book ratio of 2.98 suggesting the stock is closer to book value. The P/FCF stands at -0.03, also above market averages.

Dividend & Fair Value

Coya Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $3.39. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Coya Therapeutics, Inc. generated EPS of -$1.10 over the past year. Five-year average earnings growth is -89.45%. Wall Street analysts project EPS growth of -5.98% annually over the next five years. The latest quarter delivered EPS of -$126.45. The next quarter is forecast at -$0.27. Next year's EPS is expected at -$21.62. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 31 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $18.00 to $14.00. The high target offers 271.9% upside. The low target suggests 189.26% downside. The mean target is $15.97. This offers 229.96% upside. Coya Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by -632341.85%. The prior quarter beat by 63.64%. Over the last six quarters, Apple has recorded several small beats. These include 35.71% in August 12, 2024.

Shareholding & Insider Activity

Coya Therapeutics, Inc. has 16.73 million shares outstanding. The public float is 12.63 million shares, elevated short interest at 1.40% of float. This equals 218.34 thousand shares. The short ratio is 3.13 days. Institutional investors hold 29.09% of the float. Insiders own 7.12%. Lee Ann holds 17.48 thousand shares, Swaminathan Arun has 10.00 thousand shares and SNYDER DAVID S has 8.80 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, Coya Therapeutics generated $6.00M in revenue, or $0.59 per share. Gross margin was 99.54%, operating margin -122.62%, and net profit margin -133.08%. Returns are negative, with ROA at -19.35% and ROE at -22.41%.
On valuation metrics, Coya Therapeutics trades at a P/E of -4.41, P/S of 20.23 and P/B of 2.98. The current ratio is 8.73 and quick ratio is 8.73. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -56.63 days , indicating it collects cash faster than it pays suppliers.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Coya Therapeutics posted revenue of $6.00M, down slightly from $0.00 in the prior quarter. Gross profit was $5.97M (margin 99.54%). Operating income was - $7.36M (margin -122.6%). Net income was- $7.99M (EPS - $0.79).
The company ended the quarter with $32.63M in cash and short-term investments, a total debt of $0.00, and net debt of - $32.63M. Total assets were $41.27M, with equity of $35.65M. Financials further reflected weakness, with operating cash flow of - $11.19M, free cash flow of - $11.19M, and capital expenditures of $0.00.

Price Forecast & Outlook

Our AI price prediction model suggests that Coya Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.58%, with price expected at $4.57 by February 20, 2026, within a range of $4.26 to $4.88 3-Month Outlook: Projected fall of -22.52%, reaching $3.75 by May 06, 2026, with a range of $3.53 to $3.92. 1-Year Outlook: Projected gain of 143.8%, with price at $11.80 by February 05, 2027, within a range of $4.29 to $16.63.

Key Takeaways

Coya Therapeutics, Inc. (NASDAQ:COYA) shares are down -22.76% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Coya Therapeutics, Inc. trading at a premium to the broader market with a P/E of -4.41. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $16.00, suggesting 230.58% upside. Our AI forecast model points to short-term weakness (-5.58% over two weeks), a medium-term fall (-22.52% over three months), and a longer-term gain (143.8% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Coya Therapeutics, Inc. (COYA) stock price?

Coya Therapeutics, Inc. (NASDAQ: COYA) stock price is $4.84 in the last trading session. During the trading session, COYA stock reached the peak price of $4.88 while $4.43 was the lowest point it dropped to. The percentage change in COYA stock occurred in the recent session was 9.5% while the dollar amount for the price change in COYA stock was $0.42.

COYA's industry and sector of operation?

The NASDAQ listed COYA is part of Biotechnology industry that operates in the broader Healthcare sector. Coya Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of COYA?

Dr. Fred Grossman D.O., FAPA
Pres & Chief Medical Officer
Dr. Howard Berman Ph.D.
Chairman & Chief Executive Officer
Mr. Aaron Thome Ph.D.
Head of Neuroinflammation Platform
Dr. Adrian J. Hepner M.D., Ph.D.
Pres & Chief Medical Officer
Dr. Gregory MacMichael Ph.D.
Chief Technical Officer
Mr. David S. Snyder
Chief Financial Officer & Chief Operating Officer
Dr. Michelle Frazier Ph.D.
Senior Vice President of Regulatory Affairs
Dr. Arun Swaminathan Ph.D.
Chief Bus. Officer

How COYA did perform over past 52-week?

COYA's closing price is 22.84% higher than its 52-week low of $3.94 where as its distance from 52-week high of $8.29 is -41.62%.

How many employees does COYA have?

Number of COYA employees currently stands at 8.

Link for COYA official website?

Official Website of COYA is: https://www.coyatherapeutics.com

How do I contact COYA?

COYA could be contacted at phone 800 587 8170 and can also be accessed through its website. COYA operates from 5850 San Felipe Street, Houston, TX 77057, United States.

How many shares of COYA are traded daily?

COYA stock volume for the day was 110.27K shares. The average number of COYA shares traded daily for last 3 months was 240.65K.

What is the market cap of COYA currently?

The market value of COYA currently stands at $80.42M with its latest stock price at $4.84 and 16.62M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	8
Beta	0.26
Sales or Revenue	$6.00M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

COYA Company Profile and Key Details

Coya Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Company Overview

Earnings & Analyst Outlook

Valuation Metrics

Key Takeaways

Price Forecast & Outlook